Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Azenta, Inc. filings on SEC EDGAR ↗
Azenta reported fiscal fourth quarter and full year 2026 results, with Q4 revenue growing 5% year-over-year to $167 million. The company completed the sale of its B Medical Systems business during the year and is focusing on driving organic growth and profitability in its Multiomics and Sample Management segments for fiscal 2027.
Term
FY2026
“We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency.”
Dr. Martin Madaus, Interim President and Chief Executive Officer
“Fiscal 2027 is about consistent execution and accelerating performance. We are focused on driving organic growth, expanding profitability and cash generation, and executing on our strategic initiatives.”
Dr. Martin Madaus, Interim President and Chief Executive Officer
Azenta acquired SynPlexity Inc., a synthetic biology company specializing in high-throughput gene libraries, and entered into an exclusive licensing and supply agreement with Elegen Corp. for its cell-free DNA manufacturing technology. The combined strategic investments involve an expected capital deployment ranging from $32 million to $71 million to expand Azenta's GENEWIZ gene synthesis capabilities and regional production capacity.
Azenta, Inc. announced a restructuring plan for its Multiomics segment involving workforce reductions and the closure of three North American laboratory sites. The company expects to incur pre-tax charges between $11 million and $13 million, including $9 million in asset impairments, while targeting $11 million in annualized cost savings.
Azenta, Inc. entered into a letter agreement with Dr. Martin D. Madaus setting his compensation as Interim President and CEO, including a $600,000 base salary, a 100% cash performance bonus, and $1.2 million in restricted stock units. Additionally, the company approved one-time RSU retention awards for other named executive officers, including $1.0 million for CFO Lawrence Lin.